NXGL vs XTLB vs BFRI vs AEYE vs DERM

For growth investors, NEXGEL, Inc.

(NXGL) is the stronger pick with 112. 5% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). Analysts rate Journey Medical Corporation (DERM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Journey Medical Corporation (DERM) delivered a total return of -46.

6%, compared to -98. 7% for Biofrontera Inc. (BFRI). Over 10 years, the gap is even starker: AEYE returned +96. 5% versus BFRI's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), NEXGEL, Inc.

(NXGL) is the lower-risk stock at 0. 85β versus AudioEye, Inc. 's 2. 18β — meaning AEYE is approximately 158% more volatile than NXGL relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 128% for Journey Medical Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NEXGEL, Inc.

(NXGL) is pulling ahead at 112. 5% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: Biofrontera Inc. grew EPS 100. 0% year-over-year, compared to -242. 9% for Journey Medical Corporation. Over a 3-year CAGR, NXGL leads at 77. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AudioEye, Inc.

(AEYE) is the more profitable company, earning -7. 6% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps -7. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AEYE leads at -7. 9% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, NEXGEL, Inc.

(NXGL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 85)). AudioEye, Inc. (AEYE) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NXGL: -83. 1%, AEYE: +96. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NXGL (Healthcare) and XTLB (Healthcare) and BFRI (Healthcare) and AEYE (Technology) and DERM (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NXGL is a small-cap high-growth stock; XTLB is a small-cap quality compounder stock; BFRI is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock; DERM is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.